Drug Profile
Research programme: oligonucleotide-based therapeutics - Synthena
Alternative Names: SYN 416; SYN 510Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Synthena
- Class Antisense oligonucleotides; Oligonucleotides
- Mechanism of Action Antisense RNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in Switzerland
- 28 Feb 2017 Preclinical trials in Duchenne muscular dystrophy in Switzerland (Synthena pipeline, February 2017)